Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 25Leukemia 9Leukemia, Myeloid, Acute 8Burkitt Lymphoma 7Recurrence 4Leukemia, Biphenotypic, Acute 4Myelodysplastic Syndromes 3Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Down Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Lymphoproliferative Disorders 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic 1Immunoproliferative Disorders 1Hypersensitivity 1Hematologic Neoplasms 1

Interventions

fludarabine phosphate 41Cyclophosphamide 31Mycophenolic Acid 25Whole-Body Irradiation 23Peripheral Blood Stem Cell Transplantation 21Cyclosporine 17Rituximab 16Tacrolimus 15fludarabine 14Antilymphocyte Serum 14Busulfan 12Filgrastim 10Cyclosporins 10Methotrexate 8Sirolimus 7Therapeutics 6Melphalan 5Granulocyte Colony-Stimulating Factor 5Cytarabine 5Cord Blood Stem Cell Transplantation 5ibrutinib 4Psychiatric Rehabilitation 4Pharmacogenomic Testing 4Lenalidomide 4Carboplatin 4Allopurinol 4alvocidib 3Thiotepa 3Flow Cytometry 3Etoposide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic × asparaginase erwinia chrysanthemi recombinant × Other hematologic neoplasm × Clear all
NCT02718755 2018-06-26

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

M.D. Anderson Cancer Center

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡